ELEVAI Labs Inc.’s Post

MAIT (Mucosal-Associated Invariant T) cells are abundant in mucosal and barrier tissues, with strong potential for tumor infiltration and efficient activation in inflammatory environments. This makes the liver cancer microenvironment favorable for MAIT cell activation and recruitment. GPC3 is a well-known tumor-associated antigen widely expressed in hepatocellular carcinoma. While MAIT cell redirection may exhibit lower cytotoxicity than CD8+ T cells, it offers the advantage of selectively activating the intended T cell subtype, enabling a more focused therapeutic approach. BMX-502 appears to have a well-matched pairing of indication (hepatocellular carcinoma), target (GPC3), and modality (MAIT TCE). However, its true clinical potential must be validated through future clinical data.

Thoughts on this? >> ESMO24 Preview 1 – ADC challenges and opportunities >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #biotech #competitivemarketing #pharma

Thoughts on this? >> ESMO24 Preview 1 – ADC challenges and opportunities >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #competitivemarketing #pharma #healthcare

Ipsen announces global licensing agreement with Biomunex, adding a new pre-clinical T cell engager (TCE) to our growing TCE portfolio.    Learn more: https://lnkd.in/eqPcMTTV

Earlier this month, the FDA's CBER Office of Therapeutic Products hosted a webinar to discuss the recently finalized guidance for CAR T cell product development. One key takeaway from the virtual session was that Chain of Identity (COI) management is essential for IND applications: “Maintenance of the Chain of Identity should be described in the IND and validated for licensure.” The good news is - our supply chain orchestration system, OCELLOS, provides a seamless COI audit trail, which aligns with FDA expectations. Book a demo today to see OCELLOS could help scale-out your therapies: https://loom.ly/XvieiLU #CGT #FDA #COI #OCELLOS #CellularOrchestration #DigitalSupplyChain

Thoughts on this? >> Mark Alles’ ADC bet TORL poaches J&J medical exec; Samsung Bioepis makes historic CEO appointment >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #productmarketing #biotech #pharmaceutical #healthcare

The EC has fined Teva EUR462.6 million for misusing the patent system by engaging in a “divisionals game” as well as disparaging a rival medicine. Read about the EC’s concerns and the implications for pharma companies in our blog post: EU Commission issues EUR462.6 million antitrust fine in landmark decision on ‘divisionals game’ and disparagement. https://lnkd.in/dKzmUDk5 https://lnkd.in/d_nRD3tz

PTA is now available for more patents again. The CAFC has modified its earlier In re Cellect holding in ALLERGAN USA, INC. v. MSN LABORATORIES which was decided on August 13, 2024. The Allergan decision modifies In re Cellect by holding that “first-filed, first-issued" patents cannot be subjected to obviousness-type double patenting (OTDP) rejections over later-filed, later-issued patents that have the same priority date. Allergan therefore permits PTA to be maintained in a "first" patent. This decision is a win for patent owners. https://lnkd.in/gwTRxeuj

Warren, others urge government to allow generics to Novo's blockbuster GLP-1s ahead of CEO hearing head of a Senate hearing centered on high prices for Novo Nordisk’s in-demand semaglutide medications, lawmakers are pressing the government to use its “march-in” rights and allow generic versions of the drugs to enter the market. Elizabeth Warren, D-Massachusetts, Rep Lloyd Doggett, D-Texas, and other legislators Eleanor Holmes Norton, Jeffrey A. Merkley, Sheila Cherfilus-McCormick, JD, Ro Khanna, Pramila Jayapal, Cori Bush, Mark Pocan, Congresswoman Jan Schakowsky, Rashida Tlaib, Mark Takano, Rosa L. DeLauro, Greg Casar, and Barbara Lee penned a letter to secretary of the U.S. Department of Health and Human Services (HHS), Xavier Becerra, urging the agency to use its authority to dole out licenses to generic semaglutide makers in order to promote competition and bring down prices. United States Senate, U.S. House of Representatives Manufacturers will frequently cite the cost of innovation and the need to recoup research and development costs as the reason for charging sky-high prices. Yet, time and again, this is debunked. In the case of Ozempic and Wegovy, the manufacturer has earned over $38 billion in revenue from these two drugs and Goldman Sachs Research predicts revenue will reach $100 billion within this decade.11 Meanwhile, last year, the manufacturer spent nearly twice as much on enriching its shareholders with stock buybacks and dividends ($8.95 billion) than on research and development ($4.71 billion). “By utilizing your competitive licensing authority to permit generic competitors to Wegovy and Ozempic, you can stabilize supplies at a time of enormous demand and lower outrageous prices that have severely limited access to these life-changing drug,” the lawmakers wrote. "March-in" rights were introduced as part of the Bayh-Dole Act of 1980, enabling the government to grant licenses for any patented invention that is “used or manufactured by or for the United States” under certain circumstances. The move has never been used despite numerous attempts to pressure the government into using the legal authority. https://lnkd.in/eBM99ZpT https://lnkd.in/eik3Rbv2

August 2024 Annotated Searchable Patent Table | https://lnkd.in/dWDUxHQi We know keeping up with the latest developments in drug discovery can be a challenge, so we’ve simplified the process for you. We’ve reviewed thousands of newly published drug discovery IP documents to bring you a curated list of over 200 key patents and applications released in August 2024. Each entry comes with detailed commentary to help you navigate the content quickly and efficiently. We also have a collated database of all our curated patent selections which allows you to see longer term-industry trends in therapeutic area and target selection to give your drug discovery project the competitive edge you've been looking for. Read it on Drug Hunter | https://lnkd.in/dWDUxHQi